F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer

Inclusion Criteria

• •Subjects with measurable brain metastases of at least 1 cm in any plane based on anatomic imaging.
• •Subjects with prior resection of brain metastases with progressions on brain MRI.
• •Histologic confirmation of breast cancer.
• •Age of study subject must be \> 18 years.
• •ECOG Performance Status ≤ 2.
• •Ability to undergo brain MR and PET imaging
• •Study subjects must have normal organ and marrow function as defined below:
• •WBC \>2,000/mmᶟ, platelets \>90,000/mmᶟ, total bilirubin \<2.0 mg/dl, creatinine \<2.0 mg/dl.
• •The effects of EF5 on the developing human fetus are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation (1 month). Should a woman become pregnant pr suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of childbearing potential will have a urine pregnancy test the day of the F18 -EF5 PET scan prior to the F18 -EF5 injection.
• •Ability to understand, participate and provide a documented signed informed consent.
• •Subjects who are allergic to gadolinium will have MRI scans without gadolinium contrast.